56,57 Comparison of Hydroxyurea, Interferon Alfa, and Imatinib Mesylate for the Treatment of CML. Blast-phase CML is resistant to both hydroxyurea and interferon alfa. Multiagent chemotherapy ...

The impressive effects of the tyrosine kinase inhibitor STI571 (imatinib mesylate) in chronic myeloid leukemia were confirmed in the large trial by Kantarjian et al. (Feb. 28 issue). 1 We would ...

The objectives of this phase 2 study were to determine in children with CML receiving imatinib mesylate the hematological, cytogenetic and molecular response rate, the time and duration of ...

Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...

Imatinib mesylate (Glivec; Novartis, Basel, Switzerland) is a potent and selective inhibitor of the tyrosine kinase activity of BCR-ABL, which is a chimeric oncoprotein generated by reciprocal ...

SOURCE Sun Pharma Imatinib Mesylate is the therapeutic equivalent to Gleevec® for indications approved by FDA NEW JERSEY, Feb. 1, 2016 /PRNewswire/ -- Sun Pharma announced launch of Imatinib ...

Imatinib mesylate, also known as Gleevec, is showing early signs of promise in preclinical trials against Ewing's sarcoma, a bone tumor in children and adolescents. In a study in the November 20 ...